Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C

BJU International

Volumn 107, Issue 7, 2011, Pages 1154-1161

  Verma, Avanti ^a   Degrado, Justin ^a   Hittelman, Adam B ^a   Wheeler, Marcia A ^a   Kaimakliotis, Hristos Z ^a   Weiss, Robert M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bladder cancer; intravesical instillation; mitomycin C vascular endothelial growth factor; vascular endothelial growth factor 2

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; MITOMYCIN C; SMALL INTERFERING RNA; SODIUM CHLORIDE; SURVIVIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CANCER CELL; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; TISSUE LEVEL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA IN SITU; CARCINOMA, TRANSITIONAL CELL; FEMALE; MITOMYCIN; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79953182342     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09543.x     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al,. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49
2. Parkin DM,. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008; 218: 12-30
3. Hayat MJ, Howlader N, Reichman ME, Edwards BK,. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12: 20-37 (Pubitemid 46143500)
4. Alexandroff AB, Jackson AM, O'Donnell MA, James K,. BCG immunotherapy of bladder cancer. 20 years on. Lancet 1999; 353: 1689-94 (Pubitemid 29224536)
5. Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H,. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy with Bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder carcinoma. Eur Urol 2007; 52: 1123-29
6. Malmstrom PU, Sylvester RJ, Crawford DE, et al,. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical MMC versus Bacillus Calmette-Guerin for non-muscle-invasive Bladder cancer. Eur Urol 2009; 56: 247-56
7. Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D,. VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003; 22: 3361-70 (Pubitemid 36713733)
8. Fischer C, Mazzone M, Jonckx B, Carmeliet P,. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8: 942-56
9. Crew JP, O'Brien T, Bicknell R, et al,. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999; 161: 799-804 (Pubitemid 29422369)
10. Inoue K, Slaton JW, Karashima T, et al,. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6: 4866-73 (Pubitemid 32110431)
11. Jeon SH, Lee SJ, Chang SG,. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 2001; 8: 1265-7
12. Jones A, Fujiyama C, Blanche C, et al,. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res 2001; 7: 1263-72 (Pubitemid 32708679)
13. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H,. Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 2001; 166: 1275-9 (Pubitemid 32862155)
14. Pavlovich CP, Kraling BM, Stewart RJ, et al,. BCG-induced urinary cytokines inhibit microvascular endothelial cell proliferation. J Urol 2000; 163: 2014-21 (Pubitemid 30366804)
15. Morgan BE, Salup R, Morgan MB,. Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder. Urol Oncol 2002; 7: 67-72
16. Altieri DC,. New wirings in the survivin networks. Oncogene 2008; 27: 6276-84
17. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC,. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-8 (Pubitemid 32095036)
18. Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM,. Effect of intravesical treatment with Bacillus Calmette-Guerin and MMC on urinary survivin levels and outcome. J Urol 2003; 170: 230-4 (Pubitemid 36734468)
19. Shariat SF, Casella R, Khoddami SM, et al,. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004; 171: 626-30 (Pubitemid 38090444)
20. Schultz IJ, Kiemeney LA, Witjes JA, et al,. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23: 3327-31 (Pubitemid 36975431)
21. Swana HS, Grossman D, Anthony JM, Weiss RM, Altieri DC,. Tumor content of the anti-apoptosismolecule survivin and recurrence of bladder cancer. New Engl J Med 1999; 341: 452-3 (Pubitemid 29362524)
22. Takizawa BT, Uchio EM, Cohen J, Wheeler MA, Weiss RM,. Survivin siRNA reduces TNF receptors mRNA and protein in T-24 cells. Cancer Invest 2007; 25: 678-84
23. Filleur S, Courtin A, Ait-Si-Ali S, et al,. siRNA mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003; 63: 3919-22 (Pubitemid 36917906)
24. Hameed DA, el-Metwally TH,. The effectiveness of retinoic acid treatment in bladder cancer: impact on recurrence, survival and TGFalpha and VEGF as end-point biomarkers. Cancer Biol Ther 2008; 7: 92-100 (Pubitemid 351590459)
25. Olsson LE, Wheeler MA, Sessa WC, Weiss RM,. Bladder instillation and intraperitoneal injection of Escherichia coli lipopolysaccharide up-regulate cytokines and iNOS in rat urinary bladder. J Pharmacol 1998; 284: 1203-8 (Pubitemid 28130852)
26. Xia G, Kumar SR, Hawes D, et al,. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 2006; 175: 1245-52
27. Szarvas T, Jager T, Totsch M, et al,. Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 2008; 14: 8253-62
28. Liu L, Zhu D, Gao R, Guo H,. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. Urol Int 2008; 81: 72-6
29. Saban MR, Backer JM, Backer MV, et al,. VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation. Am J Physiol Renal Physiol 2008; 295: 60-72
30. Saban R, Saban MR, Maier J, et al,. Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients. Am J Physiol Renal Physiol 2008; 295: F1613-23
31. Albertsson P, Lennernas B, Norrby K,. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol 2009; 48: 418-25
32. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T,. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70 (Pubitemid 38657905)
33. Krause S, Forster Y, Kraemer K, et al,. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of MMC, gemcitabine and Cisplatin. J Urol 2005; 174: 328-31 (Pubitemid 40825751)
34. Wuttig D, Kunze D, Fuessel S, et al,. Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? Int J Oncol 2007; 30: 1317-24
35. Sun HZ, Wu SF, Tu ZH,. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res 2001; 11: 107-15 (Pubitemid 33677216)
36. Bolenz C, Becker A, Trojan L, et al,. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 2007; 25: 476-82 (Pubitemid 350151900)
37. Elfiky AA, Rosenberg JE,. Targeting angiogenesis in bladder cancer. Curr Oncol 2009; 11: 244-9
38. Osai WE, Ng CS, Pagliaro LC,. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 2008; 19: 427-9